Medical Advocates
Stavudine (Zerit)
 
Pediatric Index

US Treatment Guidelines
Resistance
 Adverse Events 
Dosage
 Treament





 
Stavudine Main Page Main New/Newsworthy Home Page      
Last Update:  March 16, 2007
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Clinical Pharmacology
Resistance Adverse Events  Dosage  
Resistance

 Journal Papers, Abstracts, and Commentaries  
        Selection of Zidovudine resistance mutations and escape of human immunodeficiency virus
type 1 from antiretroviral pressure in Stavudine-treated pediatric patients.
 Maxeiner HG, Keulen W, Schuurman R, et al.     
Infect Dis 2002 Apr 15;185(8):1070-6
Abstract

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals
treated with didanosine and stavudine.
Coakley EP, Gillis JM, Hammer SM.
AIDS 2000; 14: F9-15.
Abstract

Adverse Events 

    Journal Papers, Abstracts, and Commentaries

  Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+  -
lymphocyte count  and CD4+ -lymphocyte percentage at baseline and use of protease
 inhibitors   and  stavudine.
Arpadi SM,  Cuff PA, Horlick M, Wang J, Kotler DP.
 J Acquir Immune Defic Syndr 2001   May 1;27(1):30-34
 Abstract

Dosage

    Journal Papers, Abstracts, and Commentaries

  FULL-TEXT ARTICLE
 Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children
with human immunodeficiency virus infection.
Kaul S, Kline MW, Church JA, Dunkle LM.
Antimicrob Agents Chemother 2001 Mar;45(3):758-763
 Paper

Stavudine Main Page Main New/Newsworthy Home Page      

Stavudine
 Pediatric Index